Trending...
- MAG Magna Corp Targets Trillion-Dollar Opportunity by Tokenizing Rare Earth Assets Critical to AI, EVs, & Defense: MAG Magna Corp.: Stock Symbol: MGNC
- Everwild Music Festival Unveils 2026 Schedule: No Overlapping Sets, Longer Performances, and Epic Late-Night Sets!
- Special Alert! Highly Undervalued Stock: $317M Revenue in 2025 for Telecom Leader IQSTEL, Inc. (N A S D A Q: IQST)
RALEIGH N.C. & DURHAM, N.C.--(BUSINESS WIRE)--NovaQuest Private Equity ("NovaQuest") today announced its strategic growth equity investment in Pro-ficiency, LLC ("Pro-ficiency"), a leading provider of tech-enabled training and compliance solutions for clinical trial investigators and site staff.
Based in Durham, NC, Pro-ficiency provides innovative, virtual simulation training and HR compliance solutions for clinical trials, supported by original content creation and analytics services. Leading pharmaceutical companies engage Pro-ficiency to deploy customized, study-specific training solutions that improve learning retention and strengthen compliance among investigators and site staff. The company's platform also provides sponsors and CROs with real-time analytics that help to predict and avoid study errors and protocol violations, ultimately reducing the time, cost, and failure points of clinical trials. This integrated suite of services provides a compelling value proposition to its pharmaceutical customers.
"Pro-ficiency is excited to partner with NovaQuest, a firm with unparalleled global pharma and life sciences relationships and a proven track record of successfully supporting market-leading businesses in their next phase of growth," said David Hadden, Co-Founder of Pro-ficiency. "With NovaQuest's growth equity investment, Pro-ficiency is well-funded to continue changing the paradigm of clinical trial training."
More on ncarol.com
"Our customers are developing innovative products that require rigorous compliance across increasingly complex and global trials," said JoAnne Schaberick, Co-Founder of Pro-ficiency. "NovaQuest's expertise in life sciences and clinical trials will be invaluable as we continue to expand our team and offering to consistently surpass expectations and meet the needs of our valued customers."
"Dave and JoAnne are pioneers in the use of simulation-based training to improve healthcare. They have done an outstanding job developing a platform that addresses a critical, unmet need for better clinical trial training solutions," said Michael Sorensen, Partner at NovaQuest. "We look forward to supporting the Pro-ficiency team as it meets unprecedented demand for its mission-critical clinical trial training solutions."
Wyrick Robbins served as legal advisor to Pro-ficiency, and Smith Anderson served as legal advisor to NovaQuest. Deal terms were not announced.
About Pro-ficiency:
Pro-ficiency is a leading provider of tech-enabled training and compliance solutions for clinical trials. The Company provides a comprehensive suite of services, including a turn-key offering of customized, virtual training simulations, training and compliance monitoring tools, and real-time data & predictive analytics. For more information, please visit www.pro-ficiency.com.
More on ncarol.com
About NovaQuest Private Equity:
NovaQuest Private Equity is a leading investor in technology and services companies in the life sciences and healthcare sectors. NovaQuest was formed in 2000 with the vision of building an investment platform to provide strategic capital and operational leverage in partnership with strong management teams. The investment team consists of highly seasoned operational and investment professionals with significant investment experience and deep life science and healthcare expertise. Furthermore, NovaQuest benefits from an extensive network of industry experts and relationships that assist in identifying, analyzing, and growing NovaQuest portfolio companies and investments. For more information, please visit www.novaquest.com.
Based in Durham, NC, Pro-ficiency provides innovative, virtual simulation training and HR compliance solutions for clinical trials, supported by original content creation and analytics services. Leading pharmaceutical companies engage Pro-ficiency to deploy customized, study-specific training solutions that improve learning retention and strengthen compliance among investigators and site staff. The company's platform also provides sponsors and CROs with real-time analytics that help to predict and avoid study errors and protocol violations, ultimately reducing the time, cost, and failure points of clinical trials. This integrated suite of services provides a compelling value proposition to its pharmaceutical customers.
"Pro-ficiency is excited to partner with NovaQuest, a firm with unparalleled global pharma and life sciences relationships and a proven track record of successfully supporting market-leading businesses in their next phase of growth," said David Hadden, Co-Founder of Pro-ficiency. "With NovaQuest's growth equity investment, Pro-ficiency is well-funded to continue changing the paradigm of clinical trial training."
More on ncarol.com
- YOKE Expands NIL Club Into Athlete-Led Commerce With Athlete Merch Launch
- Floor Kings Announces Official Launch of Premier Epoxy Flooring Services Across Arizona
- STEM For Kids and Operation Xcel Partner to Drive Student Success Through Innovative STEM Pilot
- UK Buyers Purchase Luxury Home in Keene's Pointe, Windermere (Orlando, Florida)
- Instant IP Launches Rapid Takedown Service to Combat IP Theft, Deepfakes, and Copycat Websites
"Our customers are developing innovative products that require rigorous compliance across increasingly complex and global trials," said JoAnne Schaberick, Co-Founder of Pro-ficiency. "NovaQuest's expertise in life sciences and clinical trials will be invaluable as we continue to expand our team and offering to consistently surpass expectations and meet the needs of our valued customers."
"Dave and JoAnne are pioneers in the use of simulation-based training to improve healthcare. They have done an outstanding job developing a platform that addresses a critical, unmet need for better clinical trial training solutions," said Michael Sorensen, Partner at NovaQuest. "We look forward to supporting the Pro-ficiency team as it meets unprecedented demand for its mission-critical clinical trial training solutions."
Wyrick Robbins served as legal advisor to Pro-ficiency, and Smith Anderson served as legal advisor to NovaQuest. Deal terms were not announced.
About Pro-ficiency:
Pro-ficiency is a leading provider of tech-enabled training and compliance solutions for clinical trials. The Company provides a comprehensive suite of services, including a turn-key offering of customized, virtual training simulations, training and compliance monitoring tools, and real-time data & predictive analytics. For more information, please visit www.pro-ficiency.com.
More on ncarol.com
- Su Che Publishing Announces New Children's Book Celebrating Vaisakhi Festival
- Permian Museum Adds Photos of Fossils Discovered on a Meteorite
- This Saturday: Open House for Manalapan's Newest Single Family Home Community
- Radarsign™ Awarded Sourcewell Contract Expanding Access to Traffic Safety Solutions
- MainConcept and NETINT Bring VPU Acceleration to Easy Video API
About NovaQuest Private Equity:
NovaQuest Private Equity is a leading investor in technology and services companies in the life sciences and healthcare sectors. NovaQuest was formed in 2000 with the vision of building an investment platform to provide strategic capital and operational leverage in partnership with strong management teams. The investment team consists of highly seasoned operational and investment professionals with significant investment experience and deep life science and healthcare expertise. Furthermore, NovaQuest benefits from an extensive network of industry experts and relationships that assist in identifying, analyzing, and growing NovaQuest portfolio companies and investments. For more information, please visit www.novaquest.com.
0 Comments
Latest on ncarol.com
- Expert Law Attorneys' Top Law Firms to Know: March 2026
- Transform Your Home with G&R Landmark Renovations
- Green Office Partner Strengthens Global Operations with Mexico-Based DigitalVAAR Partnership
- P-Wave Classics Announces the Publication of The Female Quixote, Volume I, by Charlotte Lennox
- Everwild Music Festival Unveils 2026 Schedule: No Overlapping Sets, Longer Performances, and Epic Late-Night Sets!
- Riggo Production Studio Launches Monthly Content Package for Growing Brands
- Accelerating into Active Oil Production with over 100 Barrels per day now being produced as Dual-revenue engine begins Generating Cash Flow: $IBG
- Finland emerges as clear Eurovision 2026 favourite – analysis of 12 bookmakers by Vedonlyöntisivut
- Mac Mountain Selects netElastic vRouter for LightCraft Broadband-as-a-Service Platform
- 88% Revenue Growth; Charging Into the Future with Explosive Growth, Strategic EV Expansion and Infrastructure Dominance Signal a Breakout Opportunity
- Forge Resources Unlocks Major Gold-Copper System in Yukon as Drilling Success and Strategic Assets Fuel High-Impact Growth Story for: $FRGGF
- Game Day Private Jets Launches REVUP Platform to Transform Fan & Donor Travel Into a Revenue Engine for College Athletics
- Heritage at South Brunswick Team Celebrates Major Wins at NJBA Sales and Marketing Awards
- InterMountain Announces the Opening of TownePlace Suites Reno
- Home Builders Association of Durham, Orange & Chatham Counties Awards Local Scholarships
- New from Regal House Publishing, A Woman in Pink, devotion to an addict is a love story gone wrong
- SnapTax Launches AI-Powered Tax Planning Platform for Freelancers and 1099 Workers — Now Free for 90 Days
- MAG Magna Corp Targets Trillion-Dollar Opportunity by Tokenizing Rare Earth Assets Critical to AI, EVs, & Defense: MAG Magna Corp.: Stock Symbol: MGNC
- Congressional Roundtable Exposes Mental Health Crisis: More Spending and Treatment, Worse Results – CCHR Demands Accountability
- Attorney Joseph C. Kreps Files Lawsuit to Stop Alabama State Board of Pharmacy's Unlawful "Revenue-First" Rulemaking